Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MedaSorb Technologies has started enrollment in its European sepsis study, which is designed to show the effectiveness of the company's proprietary hemoadsorption device as an adjunctive treatment for acute respiratory distress syndrome and acute lung injury in the setting of sepsis.
Subscribe to our email newsletter
MedaSorb has initiated its first clinical site and will be enrolling up to a total of nine sites for the European study. MedaSorb estimates the study will take between six to nine months to complete.
Al Kraus, president and CEO of MedaSorb, said: “We are excited to start our largest clinical study to date, which, if successful, could represent a major breakthrough in the fight against sepsis.”